Search clinical trials for: Candesartan Cilexetil in formulation 2

Total 818 results

GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Hypertension

India
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Huazhong University of Science and Technology

Unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

China
AstraZeneca

Completed

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Proteinuria

Canada
Takeda

Completed

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Hypertension
Ullevaal University Hospital
Takeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHF

Completed

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Stroke

Norway
Takeda

Completed

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Hypertension

Japan
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
AstraZeneca

Completed

Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

Hypertension

United States, Hungary, Slovakia, Belgium
AstraZeneca

Completed

Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

Pediatric Hypertension

United States, Hungary, Slovakia, Belgium
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
AstraZeneca

Completed

Atacand (Candesartan) Real Life Study (Real Life)

Hypertension

Sweden
University of Arizona
Texas A&M University

Completed

A Grapefruit Feeding Trial in Healthy, Overweight Adults

Obesity | Weight Loss | Cardiovascular Risk Factors

United States
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
GlaxoSmithKline

Completed

A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

Hypertension

India
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
Takeda

Completed

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Type 2 Diabetes Mellitus and Microalbuminuria

Japan
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
University of Sydney
The George Institute for Global Health, India

Terminated

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

COVID-19 | SARS-CoV2 Infection

India
HK inno.N Corporation

Unknown

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Essential Hypertension

Korea, Republic of
Shin Poong Pharmaceutical Co. Ltd.

Completed

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Abbott
Datamap; ClinIntel; Catalent; Nuvisan

Withdrawn

A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2

Germany, Spain
Mayo Clinic

Completed

Angiotensin-II Blockade in Mitral Regurgitation

Mitral Regurgitation

United States
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Essential Hypertension

Korea, Republic of
AstraZeneca

Completed

Candesartan Effect in Second Stage Arterial Hypertension (CAESAR)

Stage II Hypertension

Korea, Republic of
Abbott
AbbVie; Parexel; Datamap; LKF Laboratorium für Klinische Forschung GmbH; Analytical... and other collaborators

Completed

Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis

Spain, Czech Republic, Hungary, Poland
HK inno.N Corporation

Completed

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets (REVERT-K)

Hypertension, Hyperlipidemia

Korea, Republic of
Hillel Yaffe Medical Center

Unknown

Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.

Skin Abnormality

Israel
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
St. Olavs Hospital
Ullevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaborators

Active, not recruiting

Candesartan for Migraine Prevention: (CandMig-3)

Migraine

Norway, Estonia
AstraZeneca

Completed

Bioequivalence Study in Healthy Subjects

Hypertension

United Kingdom
Takeda

Completed

Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)

Hypertension

Japan
Slovak Academy of Sciences

Unknown

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Hypertension

Slovakia
AstraZeneca
Takeda

Completed

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)

Heart Failure | Cohort Study

France
Kaiser Permanente
University of California, Davis

Withdrawn

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

Hepatitis C

United States
Takeda

Completed

Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"

Hypertension
AstraZeneca
Scentryphar Clinical Research; Cori Analyticals; Clínica São Lucas, Hospital... and other collaborators

Completed

Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal

Healthy

Brazil
Takeda

Completed

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

Hypertension

Ukraine, Germany
Herlev Hospital

Unknown

Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease

Cardiovascular Diseases | Kidney Failure, Chronic

Denmark
Kyoto Prefectural University of Medicine

Terminated

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS)

Myocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial Infarction

Japan
AstraZeneca

Completed

Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

Primary Hypertension

Romania
The Japanese Society of Hypertension

Unknown

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Cardiovascular Diseases | Hypertension

Japan
Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States

3

Subscribe